Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-03 11:51:56 - browse：3479

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： BioAge raises $170M for combination therapy with Zepbound

hotspot

WSS

Gilead might be held responsible for not developing a drug

BioAge raises $170M for combination therapy with Zepbound

Physician executives need more than on

What should King Charles tell the public about his cancer?

What we’ve learned from the Aduhelm mess

Chemotherapy drug shortage eases slightly but still widespread

explore

Wikipedia

hotspot

Drug repurposing or repositioning? The language matters

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Hepatitis C has a cure — but many Americans still lack access to it

Senators start work on Medicare physician payment reform

After affirmative action ruling, medical educators look to 'holistic review'

Senate panel eyes new effort on drug shortages

Medical records are filled with copy

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

knowledge

Histogen: Failed biotech offers rare public look inside

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Why did Pfizer dish out millions for a Super Bowl ad?

Medicare threatens to cut off funding for HCA's Mission hospital

Industry veterans launch new biotech VC with $310M

Biogen Alzheimer’s drug launch off to slow start

Wikipedia

entertainment

hotspot

leisure time